The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction

Stephen J. Greene, Northwestern University Feinberg School of Medicine
Mihai Gheorghiade, Northwestern University Feinberg School of Medicine
Barry A. Borlaug, Mayo Clinic and Foundation
Burkert Pieske, Medical University Graz
Muthiah Vaduganathan, Harvard Medical School
John C. Burnett, Mayo Clinic and Foundation
Lothar Roessig, Bayer Pharma AG
Johannes Peter Stasch, Bayer HealthCare AG
Scott D. Solomon, Brigham and Women’s Hospital
Walter J. Paulus, University Medical Center Amsterdam

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of the American Heart Association
Volume: Volume 2, Number 6
Publisher: American Heart Association | 2013-12, Pages e000536-e000536
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1161/JAHA.113.000536
Permanent URL: http://pid.emory.edu/ark:/25593/ft017

Final published version: http://jaha.ahajournals.org/content/2/6/e000536

Copyright information:
© 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Accessed May 12, 2019 12:35 PM EDT
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction

Stephen J. Greene, Mihai Gheorghiade, Barry A. Borlaug, Burkert Pieske, Muthiah Vaduganathan, John C. Burnett, Lothar Roessig, Johannes-Peter Stasch, Scott D. Solomon, Walter J. Paulus and Javed Butler

J Am Heart Assoc. 2013;2:e000536; originally published December 11, 2013;

doi: 10.1161/JAHA.113.000536

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://jaha.ahajournals.org/content/2/6/e000536
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction

Stephen J. Greene, MD; Mihai Gheorghiade, MD; Barry A. Borlaug, MD; Burkert Pieske, MD; Muthiah Vaduganathan, MD, MPH; John C. Burnett, Jr, MD; Lothar Roessig, MD; Johannes-Peter Stasch, PhD; Scott D. Solomon, MD; Walter J. Paulus, MD, PhD; Javed Butler, MD, MPH

Heart failure with preserved ejection fraction (HFpEF) is a growing public health problem that accounts for approximately half of all prevalent heart failure (HF). Once believed to carry a favorable prognosis compared with HF and reduced ejection fraction (HFrEF), contemporary data suggest that both groups face similar outcomes in the community setting. Although survival rates for patients with chronic HFrEF have improved in the last 2 decades with advances in drug and device-based therapies, there has been no such parallel progress in HFpEF management, and treatment remains largely limited to the active recognition and treatment of comorbidities and the use of diuretics. The prevalence of HFpEF relative to HFrEF continues to rise at \( \approx 1\% \) per year, projecting it to be the more common form of HF over the next decade. HFpEF is particularly common in the elderly and is associated with a significant risk of death, hospitalization and suboptimal quality of life. Thus, there remains an enormous unmet need for effective therapy for this group of patients.

Augmentation of cyclic guanosine monophosphate (cGMP) signaling is recognized as a potential therapeutic strategy in HFpEF based on several preclinical and clinical studies that have investigated various mechanisms and effects of cGMP enhancement. However, the recent neutral result of the Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction (RELAX) trial with the phosphodiesterase-5 (PDE-5) inhibitor sildenafil has challenged this strategy. Nevertheless, there are multiple pharmacologic strategies for cGMP pathway modulation and the effects of an intervention might vary with the mode and pathway site of action. In this article, we review the physiology and pathophysiology of the cGMP signaling pathway as it relates to HFpEF, discuss the various pharmacologic mechanisms for pathway modulation, appraise the current body of evidence for the multiple agents targeting cGMP enhancement, and outline future directions for drug development targeting cGMP enhancement as treatment for HFpEF.

The cGMP Signaling Cascade

Guanylate cyclases represent a widely distributed family of enzymes that convert guanosine triphosphate to the second-messenger molecule cGMP. The 2 primary forms are the transmembrane-associated particulate guanylate cyclase, which functions as a receptor for natriuretic peptides, and the soluble guanylate cyclase (sGC), which serves as a receptor for nitric oxide (NO) (Figure 1). The physiologic actions of cGMP are mediated through intracellular effector molecules, namely, cGMP-dependent protein kinases, cGMP-gated ion channels, and cGMP-regulated phosphodiesterases. cGMP contributes to the normal function of vital organs, and alterations in signaling have been implicated in derangements of multiple end-organ systems.

cGMP and HFpEF Pathophysiology

Once thought synonymous with diastolic dysfunction, HFpEF is now understood as a complex interplay between increased left ventricular (LV) and peripheral vascular stiffness, right and...
LV diastolic and systolic dysfunction, and chronotropic incompetence that results in abnormal ventricular relaxation and elevated LV end-diastolic pressures. This mechanistic understanding provides compelling rationale for targeting cGMP activity (Figure 2).

**Diastolic Function**

LV diastolic dysfunction is universally seen in HFpEF, and many patients have evidence of increased LV mass or relative wall thickness. sGC may reduce myofilament calcium sensitivity and exert beneficial effects on cross-bridge detachment, consistent with the ability of the NO donor sodium nitroprusside to increase cGMP generation and hasten LV relaxation. A more recently characterized mechanism may be activation of cGMP-dependent protein kinases, which have been shown to favorably influence ventricular hypertrophy, and diastolic relaxation and stiffness.

**Systolic Function**

Despite preserved LV ejection fraction, many HFpEF patients have concurrent systolic dysfunction. Regional measures of systolic function with tissue Doppler may show depression of both longitudinal and radial ventricular contractile function. Moreover, there is an elevation in end-systolic elastance and passive ventricular stiffening. In the myocardium, sGC modulates contractility and attenuates adrenergic stimulation. However, beyond these myocardial effects, reversal of cardiac endothelial dysfunction may improve ventricular performance secondary to improvement in coronary blood flow.

**Structural Cardiac Changes**

Many HFpEF patients have increased LV mass or relative wall thickness and may have concentric remodeling or hypertrophy. Total LV chamber size is typically normal or near normal, but the...
cardiomyocytes themselves may have increased diameter compared with HFrEF.45 Likewise, changes in the interstitial matrix, notably fibrosis, have been described. Experimental models of cardiac fibroblast activation have induced HF through generation of diffuse fibrosis,46 which in turn is associated with diastolic dysfunction47 and risk of arrhythmia or death.48–50 Agents targeting cGMP signaling elicit antihypertrophic effects and may favorably influence cardiac remodeling at doses not affecting blood pressure51 and attenuate cardiac fibrosis.52,53

cGMP-Dependent Protein Kinase Phosphorylation

Novel molecular understanding of cardiac mechanotransduction in normal and failing myocardium has provided an added perspective on the role of cGMP and protein kinase G (PKG) in HFrEF. Titin, a protein anchored to the sarcomere Z-line that serves as a major determinant of myocardial passive tension and stiffness, can be modulated via phosphorylation.54,55 Although the ability of cAMP-dependent protein kinase A to phosphorylate titin had been well known, it was more recently discovered that PKG can mediate similar phosphorylation in both dog and human hearts.29,56 This posttranslational modification promotes reduction in titin-based passive tension and thus may represent a promising therapeutic target for reducing myocardial stiffness. A study of myocardial biopsies among patients with HFpEF, HFrEF, and aortic stenosis evaluated the relationship between cardiac PKG, cardiomyocyte resting tension, and upstream regulation with levels of cGMP, natriuretic peptides, and oxidative stress.13 Of the 3 cohorts, HFpEF had significantly lower PKG and cGMP activity, high myocardial resting tension, and a higher degree of oxidative stress (Figure 3).13 In vitro administration of PKG resulted in significantly greater improvement in resting tension among HFpEF patients relative to those with HFrEF and aortic stenosis.

Vascular Function and Stiffness

Patients with HFpEF have significantly impaired systemic vasorelaxation with exercise, limiting cardiac output reserve under stress,57–59 and exhibit limited flow-mediated
vasodilation compared with healthy age-matched controls, implicating the role of endothelial dysfunction. Moreover, endothelial dysfunction corresponds to the severity of HF symptoms, exercise capacity, and exertional intolerance. NO-dependent regulation is a significant modulator of vascular tone, and decreased NO bioavailability in HFpEF favors vasoconstriction and vascular stiffness, amplifying afterload. Decreased NO bioavailability may also upregulate sympathetic drive and catecholamine release, and enhance endothelin-1-induced vasocontriction.

**Pulmonary Hypertension**

Among elderly patients with a normal LV ejection fraction, HFpEF is the most common cause of elevated pulmonary pressures. Elevated pulmonary artery pressure is predictive of increased mortality in HFpEF. High LV end-diastolic pressures can induce both a passive increase in pulmonary artery pressure via retrograde pressure transmission, and a reactive increase in pulmonary vascular resistance with elevations in the transpulmonary gradient out of proportion to the LV end-diastolic pressure. Enhancement of cGMP in patients with pulmonary arterial hypertension improves hemodynamics, functional status, and exercise capacity. Given the significant overlap between diastolic dysfunction and pulmonary hypertension, it has been hypothesized that cGMP modulating agents efficacious in pulmonary arterial hypertension would be beneficial in HFpEF, but this has yet to be definitively proven.

**Renal Function**

Preclinical data suggest a role for cGMP in regulation of renal function with possible mechanisms including hemodynamic-associated and hemodynamic-independent modulation of endothelial function and organ fibrosis. Direct stimulation of sGC in acute and chronic glomerulonephritis may attenuate renal dysfunction and limit progressive sclerosis and matrix deposition. Long-term sGC activation prevented increases in blood pressure, preserved renal function, improved natriuretic peptide levels, reduced LV hypertrophy, and slowed progress of renal disease in a rat model of chronic renal failure. In a canine HF model, pharmacologic targeting of cGMP increased renal blood flow and reduced mean arterial and pulmonary capillary wedge pressure without concurrent decreases in glomerular filtration rate or upregulation of the renin-angiotensin-aldosterone system.

**Other Peripheral Effects**

Endothelial dysfunction has also been associated with abnormal ergoreflex and metaboreflex actions, which lead to excessive ventilation in HF patients with exercise. Guazzi et al observed that treatment with the PDE-5 inhibitor sildenafil improved this ergoreflex activation and that the magnitude of improvement correlated with enhancement in flow-mediated arterial dilatation. In addition, recent studies have shown that many patients with HFpEF display abnormalities in peripheral oxygen utilization, uptake, or distribution in skeletal muscle that contribute to functional disability and symptoms. As NO is known to play a key role in the regulation of mitochondrial respiration, perfusion, and excitation-contraction coupling in skeletal muscle, it is plausible that cGMP enhancement would carry additional benefits for HFpEF patients outside the heart and vasculature.

**Disturbed cGMP Signaling and Strategies for Enhancement**

Recently, a novel paradigm has been proposed that supports the critical role of deranged cGMP signaling in HFpEF pathophysiology. It is proposed that the various comorbidities common to HFpEF patients foster a systemic inflammatory state contributing to endothelial dysfunction, reactive oxygen species production, nitrosative stress, and depressed NO bioavailability. This decreased NO bioavailability results in poor NO-dependent regulation, with consequent effects on cardiac hypertrophy, relaxation, and stiffness. Consistent with this paradigm, multiple preclinical and clinical trials have explored or are planning to study the role of novel therapeutic interventions at various levels in the cGMP-signaling pathway.

**Nitric Oxide Donors and Nitrates**

NO sits at the most upstream location of the cGMP pathway, and multiple studies have investigated it as a therapeutic target in HFpEF. Exogenous NO exerts a negative inotropic effect at high doses with earlier ventricular relaxation and leads to a rightward shift of the length–tension relationship. Intracoronary infusion of nitroprusside results in a decrease in LV peak systolic pressure and increases in diastolic distensibility. Aside from effects on inotropy and ventricular compliance, NO is a mediator of myocardial energetics through regulation of mitochondrial respiration, oxygen consumption, and substrate utilization. However, tolerance is a well-recognized limitation of organic nitrates, and both oxidative stress and impaired bioactivation of NO in HF may blunt the long-term effects of nitrate therapy. Furthermore, chronic treatment with nitrates may cause oxidative stress via increased expression of endothelin, hence potentially exacerbating endothelial dysfunction. Also, HFpEF patients were found to be 4 times more likely than those with HFrEF to experience a reduction in stroke volume with nitroprusside, suggesting greater vulnerability to preload.
In addition to reducing NO bioavailability, reactive oxygen species are capable of downstream cGMP pathway modulation via sGC inactivation. A reduced ferrous heme prosthetic group is required for sGC to facilitate NO-dependent cGMP stimulation. Oxidative stress shifts intracellular levels of native sGC toward the oxidized, dysfunctional, heme-free form that is unresponsive to both endogenous and exogenous NO. This concept of NO resistance provides the rationale for sGC activators that bind to the unoccupied sGC heme-binding site, thereby favoring the active enzyme state. The pharmacologic efficacy profile of cinaciguat, an intravenous sGC activator, has been explored in various in vivo models of myocardial infarction, chronic renal failure, and pulmonary hypertension. In a canine HF model, cinaciguat resulted in dose-dependent reductions in preload and afterload and a concomitant increase in cardiac output and renal blood flow without further neurohormonal activation. To date, published studies with sGC activators in human HF have been restricted to HFrEF. Although these agents demonstrate the ability to attenuate remodeling at doses that do not affect blood pressure in rodent models, a short-term infusion of cinaciguat in a phase II program of HFrEF had to be prematurely terminated partly because of excess hypotension. Future studies are required to test if the vascular and myocardial benefits seen in animal models with sGC activators can be reproduced in HFrEF patients.

In comparison to activators, sGC stimulators stimulate the enzyme by mimicking NO, thus overcoming the relative NO-deficient state. Preclinical models with these agents have demonstrated reductions in renal and cardiac fibrosis, decreased LV mass, and anti-inflammatory properties. Recently, 2 placebo-controlled phase III trials were published demonstrating beneficial effects of the sGC stimulator riociguat on 6-minute walk distance, natriuretic peptide levels, and functional class in patients with WHO Group 1 and Group 4 pulmonary hypertension. A phase IIb study in HFrEF patients testing riociguat failed to show a benefit for the primary end point of pulmonary artery pressure, but did show improvements in pulmonary and systemic vascular resistance, cardiac output, stroke volume, and quality-of-life scores. To test this pathway further in HFrEF, a trial with a once-daily oral sGC stimulator, BAY1021189, is currently under way.

Neprilysin Inhibition

Natriuretic peptide levels are a strong predictor of prognosis in HF, irrespective of LV ejection fraction. Natriuretic peptides stimulate diuresis, natriuresis, and vasodilation and may have antifibrotic and antiadrenergic effects. These physiologic effects are mediated, in part, through 3 natriuretic peptide receptors, 2 of which are transmembrane

---

sGC Activation and Stimulation

In the last 15 years, 2 classes of compounds have been discovered that are capable of modulating sGC in a NO-independent manner, the so-called sGC activators and sGC stimulators (Figure 4).
guanylyl cyclases capable of catalyzing cGMP. Neprilysin enzymatically degrades B-type natriuretic peptide (BNP), but not N-terminal pro-B-type natriuretic peptide (NT-proBNP), and compounds combining neprilysin inhibition with renin-angiotensin-aldosterone blockade are actively being tested in human HF. In HFrEF, omapatrilat, a combined neprilysin and angiotensin-converting enzyme (ACE) inhibitor, demonstrated similar effects on outcomes compared with ACE inhibitors alone, but excess angioedema halted further drug development. Recently, LCZ696, a first-in-class angiotensin receptor/neprilysin inhibitor, was tested in 301 patients with HFpEF. Compared with valsartan, the study drug led to greater reductions in NT-proBNP at 12 weeks and was safely tolerated. LCZ696 also significantly increased urinary cGMP/creatinine ratio at 12 and 36 weeks relative to valsartan (S.D. Solomon, MD, unpublished data, personal communication). Whether the observed favorable effect on NT-proBNP and cGMP will translate into improved clinical outcomes will be tested in a larger ongoing phase III program.

Future Directions With cGMP Enhancement in HFpEF

The body of evidence surrounding cGMP enhancement provides compelling rationale for further investigation of this pathway in HFpEF. Although the initial phase III attempt with PDE-5 inhibition produced a neutral result, the hypothesis of cGMP upregulation in HFpEF remains to be definitively tested. Although animal studies suggest low PKG activity in HFpEF stems largely from elevated PDE-5 activity, the aforementioned study by van Heerebeek and colleagues does not support this notion. In that study, although myocardial levels of PKG and cGMP were significantly reduced in patients with HFpEF compared with those with HFrEF and aortic stenosis, there was no difference in cardiac expression of PDE-5 between HFpEF patients and the other groups. Moreover, no differences in myocardial sGC level were observed, although it is unclear what fraction of the detected enzyme was optimally active. Taken together, these results suggest that the cGMP and PKG deficiency seen in HFpEF
manifests from reduced upstream production and bioavailability of NO or inactivation of sGC and not largely from an increased rate of cGMP degradation via PDE-5. Although plasma cGMP levels may not completely reflect tissue status, it is nevertheless not surprising that plasma cGMP level did not rise in the RELAX trial, given that it might be inefficient to inhibit an enzyme that is not upregulated and likely not primarily responsible for the cGMP deficiency. Further evidence to this effect was seen in a preclinical study by Takimoto et al, in which sildenafil produced blunting of cardiac hypertrophy and fibrosis in mice but failed to increase cGMP level. For a PDE-5 inhibitor to effectively increase cGMP expression it must rely on sufficient input at the start of the NO-sGC-cGMP pathway, and the deficiency in upstream pathway activity in HFpEF will likely limit drug efficacy. Indeed, preclinical studies in erectile dysfunction have shown the effect of sildenafil to be limited by low NO levels. Moreover, and further complicating matters, when PDE-5 is inhibited, the activity of other phosphodiesterases may be increased. For a PDE-5 inhibitor to effectively increase cGMP level, the ability of NO or inactivation of sGC and not largely from an increased rate of cGMP degradation via PDE-5 must be limited by low NO levels. 101

Given these experiences with sildenafil, interventions targeting reductions in NO bioavailability or sGC signaling are warranted to target the upstream arm of the cGMP pathway. The recently proposed novel HFpEF paradigm advocates for the central role of a systemic proinflammatory state favoring coronary microvascular inflammation and reduction in NO, cGMP, andPKG, with consequent increases in LV hypertrophy and stiffness. Among already available therapies, this paradigm supports the use of statin therapy in HFpEF given the favorable cholesterol-independent effects on endothelial dysfunction, NO bioavailability, and LV hypertrophy, fibrosis, and diastolic dysfunction, although data on hard outcomes are limited.103,104 Recent data suggest structured exercise training may be a practical means of improving peak oxygen consumption in HFpEF, perhaps through improved cGMP-mediated peripheral vascular and microcirculatory function. Dietary nitrate and nitrate therapy may also have beneficial cardiovascular effects on endothelial function and platelet activity. 106

Among investigational therapies, agents that target sGC, including sGC stimulators and activators and neprilysin inhibitors, represent promising alternatives to increase cGMP level in HFpEF. All have the advantage of an NO-independent mechanism that may circumvent problems with inflammatory-mediated NO resistance. In contrast, attenuation of cGMP catabolism with PDE5 inhibitors may facilitate increases in oxidative stress and inflammation via worsening renal function, as the high doses of sildenafil used in the RELAX trial resulted in significantly greater increases in creatinine and cystatin-C.

Clinical trials of drugs in HF have consistently shown dissociations between acute hemodynamic effects and long-term outcomes. In HFpEF, hemodynamic effects centered on vasodilation should not be a prerequisite for drug development, due in part to deficiencies in stroke volume reserve. Central hemodynamics in these patients are less volume dependent and more dependent on peripheral vasodilation. Moreover, a subset of HFpEF patients display hemodynamic derangements primarily during exercise (ie, high filling pressures and inadequate cardiac output), whereas resting hemodynamics remain relatively normal. Applying pure vasodilator therapies in these patients may improve exercise hemodynamics at the cost of excessive vasodilation, hypotension, or azotemia in the resting state. Thus, the ideal vasoactive agent would offer a modest dilatory effect and favor concurrent improvement in myocardial performance by decreasing ventricular stiffness and increasing stroke volume. Accordingly, it will be important for future trials in cGMP enhancement to dose investigational agents with this goal in mind.

Unlike acute coronary syndrome, no short-term intervention, with 1 possible exception, has been shown to offer long-term benefit in HF. Similar to HFrEF, future trials in HFpEF should focus on long-term outcomes and test therapies that are initiated during hospitalization and continued into the postdischarge period, when patients are at highest risk of poor outcomes. Likewise, future trials of cGMP augmentation should preferentially concentrate on development of oral therapies that can be used in both the hospital and outpatient settings. In this regard, focus on the upstream synthetic pathway for cGMP with use of sGC modulators and neprilysin inhibitors appears promising. Low-dose oral formulations initiated in stable hospitalized patients and continued in the ambulatory setting may be ideal to minimize the risk of hypotension and to explore long-term influences on mortality and HFpEF progression that may occur independent of any vasodilatory action. In addition, enrollment of hospitalized HF patients identifies a cohort of patients who have a more certain diagnosis and who are at high risk of subsequent events, thus improving power to detect a drug effect.

Conclusions

HFpEF is a major public health problem that lacks effective evidence-based therapies. The cGMP pathway plays a central role in derangements integral to HFpEF pathophysiology. Improved characterization of cGMP signaling and its relation to cardiac function has revealed multiple options for targeted therapeutic intervention. To date, no large phase III HFpEF trial has definitively tested the effects of pharmacologically mediated increases in cGMP activity. Future prospective studies are needed to explore the effects of pharmacologically induced increases in cGMP cell signaling on HFpEF clinical outcomes.
Disclosures
Dr Gheorghiade has been a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer HealthCare AG, CorThera, Cytokinetics, DebioPharm S.A., Errekkappa Terapeutici, GlaxoSmithKline, Ikaria, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, Solvay Pharmaceuticals, Takeda Pharmaceutical, and Trevena Therapeutics. Dr Borlaug receives research funding from the NHLBI, AtCor Medical, and Gilead and serves as a consultant for GlaxoSmithKline, Merck, Amgen, CardioKinetic, and Medscapde. Dr Roessig is a full-time employee of Bayer Pharma AG. Dr Stasch is an employee of Bayer Pharma AG and holds multiple patent applications related to soluble guanylate cyclase stimulators and activators. Dr Solomon receives research support from Novartis (> $10 000) and consulting support from Novartis and Bayer (< $10 000). Dr Butler reports research support from the NIH and the European Union and is a consultant to Amgen, Bayer, BG Medicine, Celladon, Gambro, GE Healthcare, Harvest, Medtronic, Ono Pharma, Stemedia, and Trevena. The other authors report no conflicts.

References


DOI: 10.1161/JAHA.113.000536
cGMP and HF with Preserved Ejection Fraction

Greene et al

Journal of the American Heart Association


Downloaded from http://jaha.ahajournals.org/ at Emory University on March 25, 2014


Key Words: cGMP • heart failure • phosphodiesterase 5 • preserved ejection fraction • soluble guanylate cyclase